Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 11;9(1):188.
doi: 10.1186/s13287-018-0938-6.

Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research

Lara Lopes  1   2 , Ocean Setia  1 , Afsha Aurshina  1 , Shirley Liu  1 , Haidi Hu  1 , Toshihiko Isaji  1 , Haiyang Liu  1 , Tun Wang  1 , Shun Ono  1 , Xiangjiang Guo  1 , Bogdan Yatsula  1 , Jianming Guo  3 , Yongquan Gu  3 , Tulio Navarro  2 , Alan Dardik  4   5
Affiliations
Review

Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research

Lara Lopes et al. Stem Cell Res Ther. .

Abstract

Background: Diabetic foot ulcer (DFU) is a severe complication of diabetes, preceding most diabetes-related amputations. DFUs require over US$9 billion for yearly treatment and are now a global public health issue. DFU occurs in the setting of ischemia, infection, neuropathy, and metabolic disorders that result in poor wound healing and poor treatment options. Recently, stem cell therapy has emerged as a new interventional strategy to treat DFU and appears to be safe and effective in both preclinical and clinical trials. However, variability in the stem cell type and origin, route and protocol for administration, and concomitant use of angioplasty confound easy interpretation and generalization of the results.

Methods: The PubMed, Google Scholar, and EMBASE databases were searched and 89 preclinical and clinical studies were selected for analysis.

Results: There was divergence between preclinical and clinical studies regarding stem cell type, origin, and delivery techniques. There was heterogeneous preclinical and clinical study design and few randomized clinical trials. Granulocyte-colony stimulating factor was employed in some studies but with differing protocols. Concomitant performance of angioplasty with stem cell therapy showed increased efficiency compared to either therapy alone.

Conclusions: Stem cell therapy is an effective treatment for diabetic foot ulcers and is currently used as an alternative to amputation for some patients without other options for revascularization. Concordance between preclinical and clinical studies may help design future randomized clinical trials.

Keywords: Amputation; Cell therapy; Critical limb ischemia; Diabetic foot ulcer; Diabetic wound; Stem cell therapy; Wound healing.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Diagram of study selection method and analysis. G-CSF granulocyte-colony stimulating factor; SCT stem cell therapy; PTA percutaneous transluminal angioplasty
See this image and copyright information in PMC

References

    1. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels: International Diabetes Federation, 2017. http://www.diabetesatlas.org.
    1. Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, Schaper NC. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab Res Rev. 2000;16(Suppl 1):S84–S92. doi: 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR113>3.0.CO;2-S. - DOI - PubMed
    1. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2014;37:651–658. doi: 10.2337/dc13-2176. - DOI - PubMed
    1. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ER, Whalley AM, Widdows P, Williamson S, Boulton AJ. The North-West Diabetes foot care study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19:377–384. doi: 10.1046/j.1464-5491.2002.00698.x. - DOI - PubMed
    1. Moxey PW, Gogalniceanu P, Hinchliffe RJ, Loftus IM, Jones KJ, Thompson MM, Holt PJ. Lower extremity amputations—a review of global variability in incidence. Diabet Med. 2011;28:1144–1153. doi: 10.1111/j.1464-5491.2011.03279.x. - DOI - PubMed

Publication types

MeSH terms